Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination

  • STATUS
    Recruiting
  • End date
    Feb 25, 2022
  • participants needed
    600
  • sponsor
    Kirby Institute
Updated on 25 January 2021
hepatitis
liver disease
sofosbuvir
glecaprevir/pibrentasvir
pibrentasvir
glecaprevir

Summary

A community-based "test and treat" intervention integrating point-of-care HCV RNA testing, non-invasive liver disease assessment and linkage to care will lead to a reduction in HCV prevalence among people attending Aboriginal health services.

Description

SCALE-C is an interventional cohort study recruiting people with or at risk of HCV infection from Aboriginal health services in Australia. Participants will be screened for HCV infection using point-of-care testing (anti-HCV antibody and/or HCV RNA). People with current HCV infection (HCV RNA positive) will be offered treatment with eight or 12 weeks of pan-genotypic DAA therapy, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir, as available on the PBS.

Details
Condition Hepatitis A, LIVER DISEASE, Hepatitis, Hepatitis C, Hepatitis C virus, RNA Virus Infections, Hepatitis, Viral, Human, Viral infection, Digestive System Disease, Liver Disorders, Viral Infections, hepatic disease, hepatopathy, liver diseases, hepatic diseases, hepatic pathology, digestive disorders, digestive diseases, digestive disorder, digestive disease, acute hepatitis a, a hepatitis
Treatment Glecaprevir/Pibrentasvir, Fingerstick GeneXpert HCV RNA quantitative assay, sofosbuvir/velpatesvir
Clinical Study IdentifierNCT03776760
SponsorKirby Institute
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: RNA Virus Infections or Viral infection or Viral Infections or Hepatitis A or LIVER DISEASE or Digestive System Disease or Hepatitis C virus or Liver ...?
Do you have any of these conditions: digestive diseases or a hepatitis or digestive disorder or Liver Disorders or LIVER DISEASE or Viral Infections or hepatopathy or Hepatitis or Viral i...?
years of age or older
voluntarily signed the informed consent form

Exclusion Criteria

Pregnant women
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note